Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

Correlation between Pyrazinamide Activity and pncA Mutations in Mycobacterium tuberculosis Isolates in Taiwan

Tsi-Shu Huang, Susan Shin-Jung Lee, Hui-Zin Tu, Wen-Kuei Huang, Yao-Shen Chen, Chung-Kai Huang, Shue-Ren Wann, Hsi-Hsun Lin, Yung-Ching Liu
Tsi-Shu Huang
1Section of Microbiology and Infectious Diseases, Kaohsiung Veterans General Hospital
2Department of Medical Technology, Foo-Yin Institute of Technology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan Shin-Jung Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hui-Zin Tu
1Section of Microbiology and Infectious Diseases, Kaohsiung Veterans General Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wen-Kuei Huang
3National Yang-Ming Medical College, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yao-Shen Chen
3National Yang-Ming Medical College, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chung-Kai Huang
3National Yang-Ming Medical College, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shue-Ren Wann
3National Yang-Ming Medical College, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hsi-Hsun Lin
3National Yang-Ming Medical College, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yung-Ching Liu
1Section of Microbiology and Infectious Diseases, Kaohsiung Veterans General Hospital
3National Yang-Ming Medical College, Taipei, Taiwan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ssjlee@vghks.gov.tw
DOI: 10.1128/AAC.47.11.3672-3673.2003
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A total of 76 clinical Mycobacterium tuberculosis isolates from Taiwan were tested for pyrazinamidase activity, pyrazinamide susceptibility, and pncA mutations. Frequency of resistance to PZA rose with increases in resistance to first-line drugs. Of 17 pyrazinamide-resistant strains, 7 (3 of which had not been previously described) possessed mutations in the pncA gene.

Pyrazinamide (PZA) has become increasingly important because of its ability to enhance the efficacy of isoniazid and rifampin and to allow shorter courses of therapy (2, 8, 20, 21). The unique feature of PZA is believed to be its ability to kill a population of semidormant tubercle bacilli that reside in acidic inflammatory environments (6). Unfortunately, susceptibility testing for PZA is still not sufficiently standardized to help guide therapy (7, 17, 19). Accordingly, there is a major need for more rapid and reliable tests. One approach is to detect mutations in the pncA gene. It has been reported that these mutations correlate well with a MIC of PZA of >100 μg/ml, with the frequency of pncA mutation among resistant strains (depending on the geographic area) ranging from 66.7 to 96.8% (1, 3-5, 8-12, 13-14, 18).

This study was designed to determine the frequency of PZA-resistant strains with pncA mutations among PZA-resistant and -susceptible M. tuberculosis strains isolated in Taiwan. In vitro susceptibility to PZA was correlated with PZase activity and the composition of the entire pncA nucleotide sequence. The frequency of PZA resistance among strains with various patterns of resistance to first-line drugs (isoniazid, rifampin, streptomycin, and ethambutol) was also investigated.

A total of 76 M. tuberculosis strains with variant drug susceptibility patterns isolated from 1994 to 2000 from clinical specimens collected in Kaohsiung Veterans General Hospital, Taiwan, were randomly selected. They included 27 strains susceptible to the four first-line antimycobacterial drugs, 28 multidrug-resistant (MDR) strains, and 21 strains with variable drug resistance patterns.

PZA MICs were tested by a BACTEC MGIT 960 PZA system because it requires no radioactive materials and has been shown to be as reliable as the BACTEC 460TB system (16). The susceptibility tests were performed at 100 and 300 μg/ml according to the manufacturer's instructions. The critical concentration of PZA for determination of resistance recommended by the manufacturer is 100 μg/ml. All the PZA-resistant strains were retested.

The PZase activity was assayed using the Wayne method (22). Several loopfuls of colonies were in two tubes of medium for each strain; one tube was examined after 7 days of incubation, and the other was examined after 14 days of incubation. All the strains that initially lacked PZase activity were retested.

DNAs were extracted with a Qiagen MinElute PCR purification kit (Qiagen, Valencia, Calif.) according to the manufacturer's instructions and stored at 4°C. A 720-bp region that included the entire open reading frame of pncA and 82 bp of an upstream putative regulatory sequence was amplified by PCR with the forward (P1) and reverse (P6) primers (GenBank accession number U59967 ; published by Scorpio) (18). A GeneAmp system 9600 thermocycler (Perkin-Elmer Corp., Foster City, Calif.) was used for target amplification with the following parameters: 5 min at 4°C followed by 30 cycles of 60 s at 94°C, 30 s at 63°C, and 60 s 72°C and termination with a final extension step at 72°C for 10 min. The PCR products were purified with the Qiagen MinElute PCR purification kit according to the manufacturer's instructions. The purified PCR products were sequenced in an ABI PRISM 310 genetic analyzer (Applied Biosystems, Inc., Foster City, Calif.). DNA sequencing reactions were performed with the Taq DyeDeoxy terminator cycle sequencing kit (Applied Biosystems, Inc.). Sequence data were compared with a published sequence for pncA (GenBank accession number U59967 ). Differentiation of M. tuberculosis from other members of M. tuberculosis complex was done using specific deletion profiles (15).

A total of 59 of the 76 isolates were PZA susceptible; they all had identical wild-type pncA sequences. Among the 17 PZA-resistant isolates, 7 had a pncA nucleotide sequence change and lacked PZase activity (Table 1) (isolates 1 to 7). Three of these mutations (a deletion of nucleotides 352 to 358, a G insert at nucleotide 397, and a Phe 94→Ser mutation) have not been previously reported. The Phe 94→Ser mutation was located in one of the clusters of hydrophobic residues which are close to Lys 96 and which point towards the active-site region (11). Of the resistant strains, 10 carried wild-type pncA. One strain (isolate 8) had a wild-type pncA sequence without PZase activity. The strain was MDR and formed small colonies on a 7H11 agar plate. A negative reverse transcription-PCR result indicated that there could be a mutation of a pncA-regulatory gene and that this mutation could affect expression of pncA, thereby causing PZA resistance. One strain (isolate 9) had reduced PZase activity, giving negative PZase results at 7 days but giving positive results at 14 days; the other eight strains (isolates 10 to 17) had normal PZase activity. There might be mechanisms of PZA resistance that do not affect or diminish PZase activity or expression, such as mutations leading to modification or amplification of the pyrazinoic acid (POA) target or to enhanced POA efflux. These strains may provide an opportunity to further study the alternative mechanisms of PZA resistance.

Pyrazinamidase resistance were detected in 12 of 28 MDR strains, 3 of 21 strains resistant to all of the drugs tested, and 2 of 27 strains susceptible to the four first-line antimycobacterial drugs (Table 2). We found a rise in the frequency of resistance to PZA as the number of strains resistant to the first-line drugs increased. The emergence of resistance to the first-line antituberculosis drugs has led to an increased use of PZA and other drugs to combat resistance. This finding emphasizes the importance of PZA susceptibility testing.

We found a strong (98.7%) correlation between the loss of PZase activity and the presence of a pncA genotype. We were surprised to find that only 7 out of 17 PZA-resistant strains possessed a mutation in the pncA sequence and low (88.2%) correlation between the loss of PZase activity and PZA susceptibility. This finding is in contrast to prior reports (1, 3-5, 8-12, 13-14, 18). This method is therefore not sufficiently sensitive to be used as a surrogate marker for PZA resistance in Taiwan. Nevertheless, in view of the problems of standardization with the in vitro susceptibility tests we suggest that strains with borderline or poorly reproducible susceptibility should be examined for PZase activity and that rapid automated pncA DNA sequencing should be used.

View this table:
  • View inline
  • View popup
TABLE 1.

PZase activity and changes in the pncA gene for 76 clinical M. tuberculosis isolates

View this table:
  • View inline
  • View popup
TABLE 2.

Frequency of PZA-susceptible strains according to frequency of susceptibility to first-line drugs

ACKNOWLEDGMENTS

This study was supported by Kaoshiung Veterans General Hospital grant VGHKS 91-29.

FOOTNOTES

    • Received 11 April 2003.
    • Returned for modification 6 July 2003.
    • Accepted 15 August 2003.
  • Copyright © 2003 American Society for Microbiology

REFERENCES

  1. 1.↵
    Bishop, K. S., L. Blumberg, A. P. Trollip, A. N. Smith, L. Roux, D. F. York, and P. Kiepiela. 2001. Characterization of the pncA gene in Mycobacterium tuberculosis isolates from Gauteng, South Africa. Int. J. Tuber. Lung Dis.5:952-957.
    OpenUrl
  2. 2.↵
    British Thoracic Association. 1984. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br. J. Dis. Chest78:330-336.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    Cheng, S. J., L. Thibert, T. Sanchez, L. Heifets, and Y. Zhang. 2000. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob. Agents Chemother.44:528-532.
    OpenUrlAbstract/FREE Full Text
  4. 4.
    Davies, A. P., O. J. Billington, T. D. McHugh, D. A. Mitchison, and S. H. Gillespie. 2000. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J. Clin. Microbiol.38:3686-3688.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    Hannan, M. M., E. P. Desmond, G. P. Morlock, G. H. Mazurek, and J. T. Crawford. 2001. Pyrazinamide-monoresistant Mycobacterium tuberculosis in the United States. J. Clin. Microbiol.39:647-650.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Heifets, L., and P. Lindholm-Levy. 1992. Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am. Rev. Respir. Dis.145:1223-1225.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    Heifets, L. B. 1991. Drug susceptibility in the chemotherapy of mycobacterial infections, p. 89-122. In L. B. Heifets (ed.), Drug susceptibility tests in the management of chemotherapy of tuberculosis. CRC Press, Inc., Boca Raton, Fla.
  8. 8.↵
    Hirano, K., M. Takahashi, Y. Kazumi, Y. Fukasawa, and C. Abe. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis.78:117-122.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.
    Hou, L., D. Osei-Hyiaman, Z. Zhang, B. Wang, A. Yang, and K. Kano. 2000. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. Epidemiol. Infect.124:227-232.
    OpenUrlCrossRefPubMed
  10. 10.
    Lee, K. W., J. M. Lee, and K. S. Jung. 2001. Characterization of pncA mutations of pyrazinamide-resistant Mycobacterium tuberculosis in Korea. J. Korean Med. Sci.16:537-543.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Lemaitre, N., W. Sougakoff, C. Truffot-Pernot, and V. Jarlier. 1999. Characterization of new mutations in pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. Antimicrob. Agents Chemother.43:1761-1763.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    McClatchy, J. K., A. Y. Tsang, and M. S. Cernich. 1981. Use of pyrazinamidase activity in Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility. Antimicrob. Agents Chemother.20:556-557.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Mestdagh, M., L. Realini, P. A. Fonteyne, R. Rossau, G. Jannes, W. Mijs, K. A. De Smet, F. Portaels, and E. Van den Eeckhout. 2000. Correlation of pncA sequence with pyrazinamide resistance level in BACTEC for 21 Mycobacterium tuberculosis clinical isolates. Microb. Drug Resist.6:283-287.
    OpenUrlPubMed
  14. 14.↵
    Morlock, G. P., J. T. Crawford, W. R Butler, S. E. Brim, D. Sikes, G. H. Mazurek, C. L. Woodley, and R. C. Cooksey. 2000. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. Antimicrob. Agents Chemother.44:2291-2295.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Parsons, L. M., R. Brosch, S. T. Cole, A. Somoskovi, A. Loder, G. Bretzel, D. van Soolingen, Y. M. Hale, and M. Salfinger. 2002. Rapid and simple approach for identification of Mycobacterium tuberculosis complex isolates by PCR-based genomic deletion analysis. J. Clin. Microbiol.40:2339-2345.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    Pfyffer, G. E., F. Palicova., and S. Rusch-Gerdes. 2002. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J. Clin. Microbiol.40:1670-1674.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Salfinger, M., and L. B. Heifets. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob. Agents Chemother.32:1002-1004.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    Scorpio, A., and Y. Zhang. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med.2:662-667.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    Siddiqui, S. H. 1992. Antimicrobial susceptibility testing: radiometric (BACTEC) tests for slowly growing mycobacteria, p. 14-25. In H. K. Isenberg (ed.), Clinical microbiology procedures handbook. ASM Press, Washington, D.C.
  20. 20.↵
    Singapore Tuberculosis Service-British Medical Research Council. 1981. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle62:95-102.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    Snider, D. E., J. Rogowski, M. Zierski, E. Bek, and M. W. Long. 1982. Successful intermittent treatment of smear-positive pulmonary tuberculosis in six months. Am. Rev. Respir. Dis.125:265-267.
    OpenUrlPubMedWeb of Science
  22. 22.↵
    Wayne, L. G. 1974. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. Am. Rev. Respir. Dis.109:147-151.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Correlation between Pyrazinamide Activity and pncA Mutations in Mycobacterium tuberculosis Isolates in Taiwan
Tsi-Shu Huang, Susan Shin-Jung Lee, Hui-Zin Tu, Wen-Kuei Huang, Yao-Shen Chen, Chung-Kai Huang, Shue-Ren Wann, Hsi-Hsun Lin, Yung-Ching Liu
Antimicrobial Agents and Chemotherapy Oct 2003, 47 (11) 3672-3673; DOI: 10.1128/AAC.47.11.3672-3673.2003

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Correlation between Pyrazinamide Activity and pncA Mutations in Mycobacterium tuberculosis Isolates in Taiwan
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Correlation between Pyrazinamide Activity and pncA Mutations in Mycobacterium tuberculosis Isolates in Taiwan
Tsi-Shu Huang, Susan Shin-Jung Lee, Hui-Zin Tu, Wen-Kuei Huang, Yao-Shen Chen, Chung-Kai Huang, Shue-Ren Wann, Hsi-Hsun Lin, Yung-Ching Liu
Antimicrobial Agents and Chemotherapy Oct 2003, 47 (11) 3672-3673; DOI: 10.1128/AAC.47.11.3672-3673.2003
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Amidohydrolases
antitubercular agents
mutation
Mycobacterium tuberculosis
pyrazinamide
tuberculosis

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596